Pharmaceutical Contract Development and Manufacturing Market - By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services) By End User (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users) By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 198
Status: Published
Report Code: ARI100744
Increasing demand as a consequence of ongoing patent cliff of the biologic drugs is expected to fuel demand. Presence of end-to-end service providers that are engaged in providing value added services for an integrated or risk sharing business model is expected to bolster progress in this industry. Moreover, new product launches and novel drug delivery mechanisms are anticipated to drive outsourcing demand.
The industry has been alternating between the cycles of inadequate and excessive production capacity for contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals.
Changing product pipeline is also responsible for the growth of service based market, with the rising importance of biologics, generics, and bio-similar the companies are spending more on outsourcing for their growing pipeline of biologics for the eradication of chronic disorders. “One-stop-shop” offered by the CMO’s for the promotion of portfolio of complete range of products is anticipated to influence growth of CMOs. Furthermore, differentiation and consolidation strategies adopted by companies can be attributed for projected progress.
The larger CMOs are embracing the trend of moving and focusing on the niche areas of biopharmaceutical and pharmaceutical development. They are focusing on the establishment of regulatory pathways for transgenic based product development. However, the companies are willing to restrict the outsourcing for the manufacture of complex and big moieties. They are in an opinion of in-house production rather than outsource owing to the specific requirements.
In addition to this, dynamic changes witnessed in this sector coupled with severe pressure over the margins are anticipated to restrain growth to considerable extent. Stringent and complex regulatory requirements are also attributive for steady progress.
The prominent players in the market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), BoehringerIngelheim International GmbH (Germany), and Evonik Industries AG (Germany).
Thermo Fisher Scientific is the leading player operating in the market. It has a wide geographic footprint serving over 400,000 pharmaceutical and biotech customers. The firm clocked more than USD 3 billion in revenue in 2018 from its contract development and manufacturing business. Its extensive R&D activities have enabled it to increase its capabilities in technologies, software, and services.
Analyst Commentary
Growth in this market is driven by the rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs.
On the basis of service, Pharmaceutical manufacturing services are expected to be the largest revenue contributor to the market in 2019. The large share of this segment can be attributed to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity.
On the basis of Pharmaceutical FDF Manufacturing, Parenteral/injectable manufacturing services are expected to grow at the highest CAGR during the forecast period due to factors such as the increasing need for high levels of expertise, increasing number of sterile formulations, and growing drug development activity.
On the basis of end users, the big pharma end user segment accounted for the largest share of the market in 2019. This is attributed to the emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets.
Segmentation
The global pharmaceutical contract development and manufacturing market is segmented based on service and end users. On the basis of service the market is bifurcated into Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services. The pharmaceutical FDF manufacturing services market, by service, includes Parenteral /Injectable, tablet, capsule, oral liquid, and other formulation manufacturing services. Based on end users the market is segmented into Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users.
Regional Analysis
North America dominated with respect to revenue share, however Asia Pacific is projected to grow at a surplus rate. This growth is supported by rise in number of companies outsourcing the projects in the developing economies of this region. Larger share of North American region is as a consequence of expansion of the U.S. healthcare industry. This share is anticipated to decrease to substantial extent thus driving the share of BRIC countries in this sector.
Cash rich nature of the Asian companies is responsible for the captive nature of the contract manufacturing sector. Spout of heavy investments by Asian CMOs is expected to result in exponential progress. Furthermore, Latin American market is anticipated to register substantial growth as a consequence of presence of established multinational players in this region. Major entities operating in Brazil are Novartis, Roche, and Pfizer.
Latin America holds the potential for transforming into a global hub for the development and production of pharmaceutical products. Factors that can be attributed for this transformation include robust low cost of product development.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Pharmaceutical Contract Development and Manufacturing Market
Chapter 5. Global Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
5.1. Global Pharmaceutical Contract Development and Manufacturing Market Share, By Service, 2015 - 2027 (USD Million)
5.1.1. Pharmaceutical manufacturing service
5.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Biologics manufacturing services
5.1.2.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Drug development services
5.1.3.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
6.1. Global Pharmaceutical Contract Development and Manufacturing Market Share, By End Users, 2015 - 2027 (USD Million)
6.1.1. Big pharma
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Small & mid-size pharma
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Generic pharmaceutical companies
6.1.3.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Others
6.1.4.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Pharmaceutical Contract Development and Manufacturing Market Overview, By Geography, 2015 - 2027(USD Million)
7.1. Global Pharmaceutical Contract Development and Manufacturing Market Share, By Geography, 2015 - 2027(USD Million)
7.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 8. North America Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027(USD Million)
8.1. North America Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.2. North America Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
8.1.3. North America Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
8.1.4. North America Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
8.1.4.1.3. U.S. Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
8.1.4.2. Canada Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
8.1.4.2.3. Canada Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
8.1.4.3. Mexico Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
8.1.4.3.3. Mexico Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
Chapter 9. Europe Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027(USD Million)
9.1. Europe Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
9.1.3. Europe Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
9.1.4. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
9.1.4.1.3. Germany Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
9.1.4.2. France
9.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
9.1.4.2.3. France Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
9.1.4.3. UK
9.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
9.1.4.3.3. UK Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
9.1.4.4. Italy
9.1.4.4.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
9.1.4.4.3. Italy Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users 2015 - 2027(USD Million)
9.1.4.5. Spain
9.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
9.1.4.5.3. Spain Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market Type and projections, 2015 – 2027
9.1.4.6.2. Rest of Europe Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
9.1.4.6.3. Rest of Europe Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
Chapter 10. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
10.1.4.1.3. India Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
10.1.4.2. China
10.1.4.2.1. Market Type and projections, 2015 - 2027(USD Million)
10.1.4.2.2. China Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
10.1.4.2.3. China Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
10.1.4.3. Japan
10.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
10.1.4.3.3. Japan Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027(USD Million)
10.1.4.4. South Korea
10.1.4.4.1. Market Type and projections, 2015 - 2027(USD Million)
10.1.4.4.2. South Korea Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
10.1.4.4.3. South Korea Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027(USD Million)
10.1.4.5.3. Rest of Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
Chapter 11. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
11.1.4.1.3. GCC Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
11.1.4.2. South Africa
11.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
11.1.4.2.3. South Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
11.1.4.3.3. Rest of Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
Chapter 12. South America Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Pharmaceutical Contract Development and Manufacturing Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.2. South America Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
12.1.3. South America Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
12.1.4. South America Pharmaceutical Contract Development and Manufacturing Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.5. Brazil
12.1.5.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.2. Brazil Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
12.1.5.3. Brazil Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
12.1.6. Argentina
12.1.6.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.6.2. Argentina Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
12.1.6.3. Argentina Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
12.1.7. Rest of South America
12.1.7.1. Market Type and projections, 2015 – 2027
12.1.7.2. Rest of South America Pharmaceutical Contract Development and Manufacturing Market Overview, By Service, 2015 - 2027 (USD Million)
12.1.7.3. Rest of South America Pharmaceutical Contract Development and Manufacturing Market Overview, By End Users, 2015 - 2027 (USD Million)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Type development
Chapter 14. Key Vendor Analysis
14.1. Thermo fisher scientific Inc.
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Product Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Catalent Inc.
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Product Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Lonza group Ltd.
14.3.1. Company overview
14.3.2. Financial performance
14.3.3. Product Benchmarking
14.3.4. Recent initiatives
14.4. FAMAR health care services
14.5. Consort medical plc
14.6. Others
Chapter 15. Pharmaceutical Contract Development and Manufacturing Market Cost Analysis
15.1. Pharmaceutical Contract Development and Manufacturing Market Key Type Analysis
15.1.1. Key Type
15.1.2. Price Trend of Key Type
15.1.3. Key Suppliers of Type
15.1.4. Market Concentration Rate of Type
15.1.5. Labor Cost
Chapter 16. Sourcing Strategy and Downstream Buyers
16.1. Pharmaceutical Contract Development and Manufacturing Market Chain Analysis
16.2. Upstream Type Sourcing
16.3. Pharmaceutical Contract Development and Manufacturing Market Major Manufacturers in 2021
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Client
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Technology Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Technology Progress in Related Type
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Pharmaceutical Contract Development and Manufacturing Market share, By Service, 2020 & 2027 (%)
10. Global Pharmaceutical Contract Development and Manufacturing Market share, by Pharmaceutical manufacturing service, By Service, 2015 - 2027 (USD Million)
11. Global Pharmaceutical Contract Development and Manufacturing Market share, by Biologics manufacturing services, By Service, 2015 - 2027 (USD Million)
12. Global Pharmaceutical Contract Development and Manufacturing Market share, by Drug development services, By Service, 2015 - 2027 (USD Million)
13. Global Pharmaceutical Contract Development and Manufacturing Market share, By End Users, 2020 & 2027 (%)
14. Global Pharmaceutical Contract Development and Manufacturing Market share, by Big pharma, By End Users, 2015 - 2027 (USD Million)
15. Global Pharmaceutical Contract Development and Manufacturing Market share, by Small & mid-size pharma, By End Users 2015 - 2027 (USD Million)
16. Global Pharmaceutical Contract Development and Manufacturing Market share, by Generic pharmaceutical companies, By End Users 2015 - 2027 (USD Million)
17. Global Pharmaceutical Contract Development and Manufacturing Market share, by Others, By End Users 2015 - 2027 (USD Million)
18. Global Pharmaceutical Contract Development and Manufacturing Market share, by region, 2020 & 2027 (%)
19. Global Pharmaceutical Contract Development and Manufacturing Market share, by region, 2015 - 2027(USD Million)
20. North America Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
21. North America Pharmaceutical Contract Development and Manufacturing Market share, by Countries, 2020 & 2027 (%)
22. U.S. Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
23. Canada Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
24. Mexico Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
25. Europe Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
26. Europe Pharmaceutical Contract Development and Manufacturing Market share, by Countries, 2020 & 2027 (%)
27. Spain Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
28. UK Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
29. Italy Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
30. Germany Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
31. France Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
32. Rest of Europe Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
33. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
34. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market share, by Countries, 2020 & 2027 (%)
35. China Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
36. India Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
37. Australia Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
38. Japan Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
39. Rest of Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
40. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
41. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market share, by Countries, 2020 & 2027 (%)
42. GCC Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
43. South Africa Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
44. Rest Of Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
45. South America Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
46. Brazil Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
47. Mexico Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
48. Argentina Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
49. Rest Of South America Pharmaceutical Contract Development and Manufacturing Market, 2015 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Pharmaceutical Contract Development and Manufacturing Market, 2015-2027 (USD Million)
4. Pharmaceutical Contract Development and Manufacturing requirement, by country, 2015-2027, (USD Million)
5. North America Pharmaceutical Contract Development and Manufacturing Market, By Service, 2015-2027 (USD Million)
6. North America Pharmaceutical Contract Development and Manufacturing Market, By End Users, 2015-2027 (USD Million)
7. Europe Pharmaceutical Contract Development and Manufacturing Market, By Service, 2015-2027 (USD Million)
8. Europe Pharmaceutical Contract Development and Manufacturing Market, By End Users, 2015-2027 (USD Million)
9. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market, By Service, 2015-2027 (USD Million)
10. Asia Pacific Pharmaceutical Contract Development and Manufacturing Market, By End Users, 2015-2027 (USD Million)
11. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market, By Service, 2015-2027 (USD Million)
12. Middle East & Africa Pharmaceutical Contract Development and Manufacturing Market, By End Users, 2015-2027 (USD Million)
13. South America Pharmaceutical Contract Development and Manufacturing Market, By Service, 2015-2027 (USD Million)
14. South America Pharmaceutical Contract Development and Manufacturing Market, By End Users, 2015-2027 (USD Million)
15. Global Pharmaceutical Contract Development and Manufacturing Market, Company Market Share, 2020 - 2027 (%)
16. Thermo fisher scientific Inc.: Product Benchmarking
17. Thermo fisher scientific Inc.: Financial Performance
18. Catalent Inc.: Product Benchmarking
19. Catalent Inc.: Financial Performance
20. Lonza group Ltd..: Product Benchmarking
21. Lonza group Ltd..: Financial Performance
22. FAMAR health care services: Product Benchmarking
23. FAMAR health care services: Financial Performance
24. Consort medical plc: Product Benchmarking
25. Consort medical plc: Financial Performance
The Leading Key Players in Pharmaceutical Contract Development And Manufacturing Market
Thermo Fisher Scientific Inc. (US)
Catalent Inc. (US)
Lonza Group Ltd (Switzerland)
Recipharm AB (Sweden)
Vetter Pharma International GMBH (Germany)
FAMAR Health Care Services (Greece)
AbbVie Inc. (US)
Aenova Group (Germany)
Consort Medical plc (UK)
Almac Group (UK)
Siegfried Holding AG (Switzerland)
BoehringerIngelheim International GmbH (Germany)
Evonik Industries AG (Germany).
